RT Journal Article
SR Electronic
T1 Management of anticoagulant and antiplatelet therapy in patients undergoing interventional pulmonary procedures
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 170020
DO 10.1183/16000617.0020-2017
VO 26
IS 145
A1 Vikas Pathak
A1 J. Erin Allender
A1 Mollie W. Grant
YR 2017
UL http://err.ersjournals.com/content/26/145/170020.abstract
AB There has been great progress in antithrombotic therapy over the past several years. Its use has increased with the advent of novel anticoagulants, as these medications do not require frequent blood tests for monitoring. Antithrombotic therapy is aimed at reducing the risk of thromboembolic events in patients with atrial fibrillation, coronary artery disease, deep vein thrombosis, valvular heart disease and pulmonary embolism. These patients are often critically ill and frequently undergo urgent interventions requiring discontinuation of anticoagulant or antiplatelet therapy which can increase the risk of thrombosis; however, continuing these agents can lead to increased risk of haemorrhage.The purpose of this article is to summarise the literature surrounding the safety of using antiplatelet and anticoagulant therapies in patients undergoing interventional pulmonary procedures.Available studies suggest some antithrombotic agents may be used in interventional pulmonary procedures http://ow.ly/vSF030bRqjt